Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasma kallikrein (Homo sapiens (Human)) | BDBM416721![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM439471![]() (US10633345, Compound 54e | US10633345, Compound 70...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416930![]() (1-(3-(Aminomethyl)phenyl)-N-(3-((3-bromo-4-hydroxy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416725![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416909![]() (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416933![]() (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416725![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416909![]() (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-hy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416936![]() (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416770![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416903![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416939![]() (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416770![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416903![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416942![]() (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416751![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416906![]() (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM447737![]() (US10689346, Compound 250c | US11203574, Compound 2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416751![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416906![]() (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416948![]() (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-ph...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416794![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416894![]() (1-(3-(aminomethyl)phenyl)-N-(5-((4-cyanophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416794![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416894![]() (1-(3-(aminomethyl)phenyl)-N-(5-((4-cyanophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416954![]() (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416841![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416900![]() (1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416957![]() ((+-)-1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416841![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416900![]() (1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416960![]() (1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416867![]() (1-(3-(aminomethyl)phenyl)-N-(3-((3-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416856![]() (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416867![]() (1-(3-(aminomethyl)phenyl)-N-(3-((3-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416856![]() (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416837![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416747![]() (1-(3-(Aminomethyl)phenyl)-N-(5-((cyclopropylmethox...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416837![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416747![]() (1-(3-(Aminomethyl)phenyl)-N-(5-((cyclopropylmethox...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416972![]() ((+-)-1-(3-(aminomethyl)phenyl)-N-(5-((bis(cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416973![]() ((+)-N5-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416974![]() ((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416975![]() ((+-)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-2-yl)p...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416977![]() ((+-)-N-(5-(1-acetamido-3-cyclopropyl-1-(pyridin-3-...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416975![]() ((+-)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-2-yl)p...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416979![]() ((+)-1-(3-(aminomethyl)phenyl)-5-(5-((cyclopropylme...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416980![]() ((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416981![]() ((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416983![]() ((+-)-1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
BioCryst Pharmaceuticals, Inc. US Patent | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2... | US Patent US10689346 (2020) BindingDB Entry DOI: 10.7270/Q22J6FXH | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 302 total ) | Next | Last >> |